about
Emerging drugs for uveitisCurrent approach in the diagnosis and management of panuveitis.Ocular manifestation of rheumatoid arthritis-different forms and frequencyPharmacotherapy for uveitis: current management and emerging therapy.Bilateral macular thickening in mild unilateral anterior uveitis: is HLA-B27 involved?Diagnostic techniques for inflammatory eye disease: past, present and future: a review.Increased CD40+ Fibrocytes in Patients With Idiopathic Orbital Inflammation.Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease - five new cases and reviewPharmacotherapy of scleritis: current paradigms and future directions.Biological agents for the treatment of uveitis.Biologic agents in inflammatory eye disease.Systemic treatment of vitreous inflammation.Systemic treatments for noninfectious vitreous inflammation.Biologic therapy for refractory scleritis: a new treatment perspective.Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.HLA-B27 Anterior Uveitis: Immunology and Immunopathology.Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis.Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.Bilateral uveitis following intravenous immunoglobulin administration.Psoriatic uveitis responding to adalimumab therapy.Rituximab therapy for refractory idiopathic scleritis.Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports.[Anti-TNF-α treatment for uveitis. Analysis of the current situation].
P2860
Q24630848-7C761325-A7C3-4406-BC86-EADC26898811Q33737954-B14F4959-A599-4CE4-AC19-28867EB16395Q33847956-8A2A1CAB-4E79-4C2C-B4EE-7300A9885A48Q34274075-A506FF30-DDA6-4EF0-BEC5-315F97CC236EQ34354352-07C6403E-0DDE-4F9A-83A3-92561E86136EQ34910419-20D96127-50A7-4E04-8F91-EB96E91C90EEQ35054706-E60372F2-E4B7-4AA8-B7DF-F5643B0487CAQ35064588-E69AC7AB-0335-4029-A10E-D88D356BFF27Q37236634-159E515E-4BF2-46F6-B0B8-52E73EE18E43Q37466204-E0582785-2834-4360-B088-70833C4B3565Q37984565-28C4DE8A-F0D8-49D6-AD3C-6D962902CE13Q37997772-1DA608C1-FC4C-42F6-A0AD-A56E92B21DD3Q38048774-86AAF3E6-F62A-4146-8E3B-E7C56F6C4ADEQ38172090-F5E3425D-64CD-4297-84EC-F23783CF439EQ38576234-0AD65FCB-FD44-4CA2-BCA3-0DD4EA63DE3FQ38773144-5AA27386-A9CF-4FB4-BD47-BD01A03A7980Q38849274-9234888F-F20A-46BE-8951-04FDB06741FCQ41576239-0CF474BC-D9FC-4647-A098-39145DE73591Q42539284-AA4DEF64-B333-4520-BC7B-49B94B4FE1E6Q42840690-9438F4F5-6DB0-4F05-9891-43A115D75822Q46419310-41EB8F00-EB24-43AB-9D2B-4D2C9698108EQ47108804-4E4B3CFD-7DC9-4F86-949E-E6FC5210661FQ47951671-109B0FD0-FF71-483B-BA94-D8CA6F9A096EQ51004424-C3729080-8449-41B5-80FF-ED7F9143CCE1Q51321732-EE157914-8157-45D7-A1F5-34320A215D3BQ52899661-C0AD6117-8AD2-4A48-8D13-2CDF55E66C23
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Biologic therapies for inflammatory eye disease.
@ast
Biologic therapies for inflammatory eye disease.
@en
type
label
Biologic therapies for inflammatory eye disease.
@ast
Biologic therapies for inflammatory eye disease.
@en
prefLabel
Biologic therapies for inflammatory eye disease.
@ast
Biologic therapies for inflammatory eye disease.
@en
P2093
P2860
P1476
Biologic therapies for inflammatory eye disease.
@en
P2093
Eric B Suhler
Justine R Smith
Lyndell Lim
P2860
P304
P356
10.1111/J.1442-9071.2006.01225.X
P577
2006-05-01T00:00:00Z